Substance / Medication

Undecylenic acid

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Optimizing biosensing properties on undecylenic Acid-functionalized diamond.
Zhong Yu Lin, Chong Kwok Feng, May Paul W et al. · Langmuir · 2007
PMID: 17419656Observational
Allergic contact dermatitis caused by undecylenic acid in an antifungal nail solution.
Ochando-Ibernón Gemma, Schneller-Pavelescu Luca, Vergara de Caso Eduardo F et al. · Contact Dermatitis · 2019
PMID: 30537336Case Report
Allergic contact dermatitis from undecylenic acid in a commercial antifungal nail solution.
Anguita J L, Escutia B, Marí J I et al. · Contact Dermatitis · 2002
PMID: 11918606Case Report
Antifungal Effect of Poly(methyl methacrylate) with Farnesol and Undecylenic Acid againstBiofilm Formation.
Išljamović Milica, Bonvin Debora, Milojević Milena et al. · Materials (Basel) · 2024
PMID: 39203113OtherFull text (PMC)
A facile approach to undecylenic acid-functionalized stationary phases for per aqueous liquid chromatography.
Cheng Xiao-Dong, Zhang Zheng, Li Yun-Ping · Anal Chim Acta · 2023
PMID: 37230580Other
Two-step single-reactor synthesis of oleic acid- or undecylenic acid-stabilized magnetic nanoparticles by thermal decomposition.
Nahorniak Mykhailo, Pasetto Pamela, Greneche Jean-Marc et al. · Beilstein J Nanotechnol · 2023
PMID: 36703905OtherFull text (PMC)
Novel Formulation of Undecylenic Acid induces Tumor Cell Apoptosis.
Day Zoe I, Mayfosh Alyce J, Giel Marie-Claire et al. · Int J Mol Sci · 2022
PMID: 36430646OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Undecylenic acid (substance)
SNOMED CT
386990002
UMLS CUI
C0041660

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.